Key statistics dashboard for Celularity Inc. (CELU). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking.
Stock Data
| Price | $1.29 |
| Market Cap | $37M |
| Enterprise Value | $70.6M |
| Beta | 0.70 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.35 |
| Price / Book | -0.88 |
| P/S | 1.43 |
| EV/EBITDA | -0.91 |
| EV/Sales | 2.66 |
| EV/FCF | -5.33 |
| P/FCF | -2.86 |
| Earnings Yield | -288.93% |
| FCF Yield | -36.93% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 76.04% |
| EBIT Margin | -320.00% |
| EBITDA Margin | -292.36% |
| Operating Margin | -230.92% |
| Net Margin | -345.44% |
| Return on Equity | 411.46% |
| Return on Assets | -85.45% |
| Return on Invested Capital | -151.11% |
| Return on Capital Employed | -230.74% |
Financial Health
| Current Ratio | 0.15 |
| Quick Ratio | 0.15 |
| Cash Ratio | 0.08 |
| Debt / Equity | -1.07 |
| Debt / Assets | 38.11% |
| Net Debt / EBITDA | -0.45 |
| Interest Coverage | -9.08 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -15.22 |
Per-Share Data
| Revenue per share | 1.04 |
| Book Value per share | -1.49 |
| Cash per share | 0.24 |
| FCF per share | -0.52 |
| Tangible Book Value per share | -2.08 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 2 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (1-5) | 0.33 |
Related companies: ANVS · ATNM · BCAB · BTAI · FGEN · GBIO · KZR
Explore sector: Healthcare · Biotechnology
More sections of CELU: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks